Full Transcript Introduction to Brain Imaging 0:00 Hello and welcome to the Alzheimer's Summit 2.0. 0:04 I'm here with James Hamet. 0:06 He is an innovator in the brain health space. 0:09 We're going to be talking about his invention 0:11 that is going to transform the way in which we can view 0:14 the recovery of our brains. 0:17 It's going to be an incredible session. 0:18 This is true innovation in medicine. 0:21 And, James, such a pleasure to have you here on the summit. 0:24 Thank you James. 0:25 Well, let's jump into it straight away. 0:28 I guess the first thing that I'd love to, to understand for our audience 0:31 who are watching at home, many of which are working with family members 0:35 who may be experiencing cognitive decline, experiencing themselves, 0:39 maybe there's, practitioners 0:40 and clinicians who are working on reversing cognitive decline. 0:45 I'd just like to start by you giving us a little bit of a landscape for 0:50 the world of 0:51 brain imaging, because ultimately, you know, there's 0:54 different ways in which we can understand whether the brain is healing. 0:58 Right? 0:58 There's all kinds of biomarkers 0:59 that we could look at to understand the sort of drivers of cognitive decline. 1:03 There's new biomarkers that are actually showing whether or not 1:07 the process that ends up with Alzheimer's is happening way before. 1:11 So there's a lot of really interesting biomarker work, 1:13 but you're specifically interested in visualizing the brain. 1:16 And I would say that most people who have got into this 1:19 topic would probably understand that there are different ways 1:22 to create images of the brain. 1:24 And so I'd love for you to start like, what are the ways in which we understand 1:28 the health of the brain through visual medium today? 1:31 And, and what are your thoughts on them? 1:34 Yeah, of course. 1:35 So probably the way of visualizing the brain 1:38 that's the most common place would be the MRI. 1:41 It's a it's a giant machine with spinning magnets. 1:45 And one of the ways that it works, of course, is by making your body, 1:50 not just your brain, visible on the magnetic spectrum. 1:53 It looks a lot like an X-ray. 1:55 One of the cool things about it is that it doesn't 1:57 just show you your bones, it shows you, the cellular structures. 2:01 It shows you the neurons. It's a very powerful tool. 2:04 And it's a tool that, frankly, I think everybody, if they experience 2:09 any type of brain disease 2:10 that they've had before, it's very standard, very routine. 2:13 Besides that, there are sometimes CT images, 2:16 but you also have something called a pet scan. 2:18 A lot of people know about the Pet scan, but they might not know is that 2:22 the question is actually relatively rare, in the world, and also even in the US 2:27 and the world, there's not even one Pet scan for every country. 2:31 A lot of countries, 2:32 they have to send their, their, their patients out to get the Pet scan. 2:36 And in the US, even though we have a couple hundred machines, 2:39 that's still not enough to deal with all of the patients who need brain imaging. 2:44 The most common use of the Pet scan is actually for cancer. 2:48 But that might be a little surprising, 2:50 but it's because cancer cases are also very frequent. 2:53 And then for Alzheimer's, I find that it's a very valuable test. 2:56 And that's because the Pet scan is not just giving you 2:59 a structural image of the brain, it's doing something special. 3:03 It's using a radioactive tracer 3:06 that you drink, that you inject. 3:09 And what that tracer does is it binds to certain proteins, 3:12 the proteins that you want to be measuring. 3:14 And so for that reason, there's lots of different types of Pet scans you can get. 3:17 It's not the same as an MRI where every MRI is basically the same. 3:21 But Pet scan depends on its tracers. 3:23 But what that does is it gives you an extra dimension. 3:26 Now you you have an image that's colorful. 3:28 It's not just showing you 3:29 the structure, it's also showing you the concentration of certain proteins. 3:32 And so those are the main visualization techniques that exist today.
MRI, PET, and SPECT Compared 3:37 When you're looking with MRI, what someone's typically looking for 3:40 is a stroke. 3:41 Always important to rule out a stroke. 3:43 You may if you're dealing with an Alzheimer's case. 3:45 But in the in the case of Alzheimer's, 3:47 you might use an MRI to see if the volume of the brain is changing. 3:51 You know, is the person's brain shrinking? 3:53 Obviously, if it's getting larger, that that that could be concerning. 3:56 Could be a sign of inflammation, but typically 3:59 it'll be shrinking with with a neurodegenerative disease. 4:02 But it shrinks very, very slowly. 4:04 So for that reason the MRI is typically done at the very beginning 4:07 to rule out other potential causes of symptomatic behavior of the patient. 4:12 And then also maybe very, very late, if you wanted to see, you know, 4:16 how you've changed over the past couple of years, the test that I think is 4:21 really the best to see changes over time 4:23 would be the Pet scan, if it were possible to do that more than once a year. 4:28 Yeah, yeah. 4:29 Well, just give us the lay of the land on the Pet scan. 4:31 So if someone is lucky enough to get one in America, they can't get it very often. 4:35 Is that because of a health risk or is that just availability of the machines? 4:40 Yeah. 4:40 So Pet scan is 4:43 unavailable for routine use for a variety of reasons. 4:46 One of them is, as you called out, it's the safety risk. 4:49 I already mentioned the radioactive tracer that gets used to measure the proteins. 4:53 Right? 4:53 That's a fundamental, important part of the Pet scan 4:55 and how it works and the value that it provides. 4:58 But it also introduces risk if you have too much of that tracer, 5:01 if you have too many of these tests, 5:03 you can unfortunately cause, a cancerous event for the patient as well. 5:07 So the safety guidelines for Pet scans 5:10 are only doing one per year, once every 12 months. 5:14 Those guidelines are sometimes, unfortunately, ignored. 5:17 There is a case where they're ignored for for a particular reason. 5:21 And that case is actually brain cancer, 5:23 because we know the value of the Pet scan, and we know the value 5:26 of doing this repeatedly to see how the brain is changing. 5:29 It's been accepted in the field of neuro oncology to do Pet scans 5:34 within three months of each other, and so that's accepting 5:37 the risk that it may exacerbate the cancer. 5:40 But the value of being able to do the imaging is so important. 5:44 But it's worth it. 5:44 The guidelines have not been adjusted for other conditions. 5:47 Alzheimer's, for example, 5:49 you wouldn't necessarily want the person to now also have cancer. 5:52 So for that reason, those guidelines are still there for 12 months. 5:57 Interesting. 5:57 All right. 5:58 And then just briefly before we come onto like some of that, 6:01 like I know in our space. 6:02 Well, you know, there's, there's someone who's quite well known as Daniel Ayman. 6:07 And visualization of the brain is a part of his, you know, methodology. 6:11 What are your thoughts on on that and how does that fit into the picture? 6:16 Yeah. 6:16 So that's a technology called Spect scan. 6:19 I mean, honestly, there are a lot of of these other types of scans. 6:22 There's something called a Dat scan which is for measuring dopamine. 6:25 What it comes down to is what what resolution are you looking for? 6:29 And are you interested in measuring certain proteins. 6:33 The spec is going to look a bit like a lower resolution MRI. 6:39 It might be able to show you I'm not as familiar with the Spect scan, 6:42 but it might be able to show you some things that other other tests can't. 6:45 But my understanding of it is that it's a pretty low resolution. 6:49 And it's mostly looking at structure. 6:50 So you might need, 6:53 you might be able to use it at the beginning for ruling out things. 6:56 You might be able to use it at the end 6:57 to confirm that the person's very late stage. 6:59 The middle point, I think is, is where the value might still 7:04 be competing with the Pet scan, which has higher resolution 7:07 and the proteins involved. 7:09 Yeah. 7:10 My my understanding is that it's sort of just like a sort of a broad baseline 7:13 for all the things that you've done to yourself 7:16 your whole life 7:16 shrinking the brain, you know, is the volume going down or otherwise. 7:19 But yeah, it's, it's interesting. 7:21 So look, let's get on to, you know, let's, let's, let's do visuals for people. 7:24 Yeah. 7:25 Because I think, I think a picture tells a thousand words. 7:28 Let's contextualize these things. 7:29 So this is, this is what a Spect scan looks like. 7:33 And it's looking at blood flow, which you know 7:36 often is associated with structure. 7:39 So that's one of the strong parts about the Spect scan. 7:42 But as I pointed out previously you have some information about the structure. 7:46 But this is this is very low resolution right. 7:49 Yeah. 7:49 I see that you might have like a heatmap type 7:51 of a visual, versus so here's an MRI of the brain. 7:58 Right. 7:58 I mean, this is hyper, precision on resolution. 8:03 Right. You can see all the ventricles. 8:06 You can see all the little, pathways that the brain is making. 8:11 You can see that the volume is changing. 8:13 I don't know if you can necessarily trust the volume of, of a Spect scan. 8:17 Yeah. 8:18 The last thing I want to show is what a Pet scan looks like. 8:20 Let's make it Alzheimer specific to. 8:22 So this is very similar, right. To an MRI. 8:25 The difference is that you have these colors. 8:28 And those colors are so helpful, 8:29 which is one of the reasons the Pet scan is today the gold standard. 8:33 Not only do you have some, 8:34 you have a little bit of loss of resolution sometimes, like in this one. 8:38 Not only do you have that structure that's preserved, 8:40 right, you can clearly see this is the amygdala, 8:42 but you also have these colors and those colors are so key. 8:46 The colors are showing you amyloid protein. 8:48 So here these red clumps are accumulations of amyloid. 8:53 And we can see here that it's mostly in the front of the person's brain. 8:57 It looks like it might be more on one side versus the other. 9:00 This is the type of information that that you want to have. 9:03 Right. 9:03 Because then you can see what's going on. 9:06 And if you give someone a therapy, especially a therapy that's, 9:10 you know, reducing trauma on their brain, reducing inflammation, 9:13 whether it's anti amyloid 9:14 or whether you're treating the underlying causes of the amyloid, which again 9:18 go back to stress of the brain, then you have a reduction of the amyloid.
Introducing Sarah Graham 9:23 And hopefully, you know in the case of successful therapy 9:26 you gradually see these images move towards the negative here. 9:31 This is what a healthy person's brain should look like. 9:33 Here's your of amyloid. 9:35 I just want put a little asterisks to say 9:36 that amyloid is present in most people's brains. 9:39 This is this is a golden example of somebody without amyloid. 9:44 But even people who are asymptomatic, usually their brains 9:47 look somewhere in between. 9:49 Yeah, thanks for sharing. That is actually very helpful. 9:51 And I'm really glad you shared that. 9:52 Well, look, I don't want to keep everyone in suspense any longer, you know? 9:55 Yes, you are to some degree a commentator 9:59 on the history of the way that, brains have been visualized. 10:02 But you're actually an inventor who has invented a new way to visualize the brain. 10:07 So, you know, share 10:09 with us a little bit about, you know, your invention, where it came 10:12 from, and ultimately, like, why you think it's particularly relevant 10:16 to this conversation, which is the reversal of Alzheimer's, 10:19 which has never really been appropriate before. 10:22 Ultimately, recently we had the first preprint to show that, 10:26 you know, that that precision medicine approach can improve people's brain 10:29 health, can, in some cases, reverse Alzheimer's. 10:32 And so I'd love to love to just to you up to share 10:36 like how you got here and where are you and why you're interested in this field. 10:40 Yeah. 10:40 Of course what I, you know, I guess drumroll. 10:43 What I've invented is a new way to visualize the brain. 10:48 And the exciting thing about it is it it doesn't require a new level of education, 10:53 you know, it doesn't give you information that that you might not be accustomed to. 10:58 It actually solves the problem of the Pet scan. 11:01 And that problem, again is the use of the radioactive tracers. 11:04 It makes the test really expensive. 11:06 It makes the test unsafe for repeated use. 11:09 And then, you know, besides that, the Pet 11:11 scan is also impractical to have at a clinic. 11:14 So, you know, if I if I'm if I'm a physician treating Alzheimer's, 11:17 then the challenge that I have is what to do with my patient. 11:20 The patient comes in, I give them a treatment. Right. 11:22 That part's easy. 11:23 A person probably has come in with a diagnosis 11:25 in many cases, or at least a suspected diagnosis. 11:29 What happens when that patient comes back a month 11:31 later and says, hey, I don't know if I want to keep doing this treatment. 11:36 I don't know if it's working. 11:37 You know, there might be side effects, it might be difficult, you know, if 11:40 it's dietary, exercise, sleep, you know, there's some behavioral challenges. 11:44 The person might be ready to throw in the towel. 11:47 What can you do for that person? 11:49 You can send them away to get a Pet scan to another facility 11:52 that they might not come back from. 11:54 You can, you know, try to just ask them to have faith. 11:57 And of course, if they've already had a Pet scan, 11:59 then then you know, the first options on the table. 12:01 Well, so what I, what I'm doing here is called, evoked potential tomography. 12:05 The technology is called Sarah Graham. 12:07 And it allows you to know what a Pet scan might 12:10 look like for your patient if they were to get one today, 12:13 but they can do it in office without the tracers. 12:16 And it's really inexpensive available equipment so we can ship it to you. 12:21 It's called Sarah Graham. 12:22 You can do it in a, you know, in a closet. 12:25 I mean, it's really small. It's a suitcase. 12:27 And inside you have some hardware, you have a laptop, you know, software. 12:32 And what that test will do is it 12:34 will look at the structural integrity of the neurons in your brain 12:38 and how they wire together, and it'll give you images 12:43 that are very accurate estimates of what the Pet scan would give you today. 12:48 Beautiful. 12:49 I know, there's one 12:50 in Doctor Burke's office who's the co-host here of this, of this summit. 12:54 I know you've got a few 12:55 and some leading Alzheimer's reversal clinics around the country. 12:59 Why is it particularly interested to interesting to doctors and practitioners 13:03 that are in this emerging field of, let's call it reversing cognitive decline? 13:07 Yeah. 13:08 So it's a fairly powerful technology in 13:11 that it gives you many different endpoints with the same test. 13:15 It can tell you what type of symptoms the person might be experiencing. 13:19 It can of course give you those image estimates that are very valuable. 13:22 I mean, the biomarkers that we have under the hood 13:25 are the measurement of the integrity of the network. 13:28 So we are directly measuring how the neurons are wired. 13:32 And when you have a neuro traumatic event, whether that's a concussion 13:35 or whether that's a gradual onset of disease like Alzheimer's, 13:38 we are measuring it at the fundamental level, right. 13:42 Because if you're measuring how the neurons are connected, 13:45 you do know the downstream symptoms of the disease. 13:48 You do know how the disease is progressing. 13:51 And then when you are administering a therapy right at your office, 13:55 you now have a way of seeing that therapy work in real time. 13:59 So you can do this test this month, next month, a month after that, 14:03 you can share the results of the patients, and they can see the picture 14:06 and they understand. 14:08 They see that it's their brain. 14:09 They know that red means bad, and they see that 14:12 the clumps of red are shrinking and getting smaller. 14:15 Over time, they see themselves returned to health. 14:18 And what's been most exciting for me is over the past couple of months, 14:22 I, you know, the people using the technology have of course, 14:25 been communicating with me and sharing how the technology is 14:29 in fact showing improvement for almost all of their patients. 14:33 Of course, there are sometimes cases where the treatment 14:36 was not the right treatment for the patient. 14:38 And so in those cases, you know, the patient might appear to stagnate. 14:43 But that is the purpose of the technology 14:45 is to answer the question of is therapy working? 14:48 And if it's not to help the doctor strengthen that trust 14:51 that they have from the patient and come up with new strategies 14:54 to treat them, because every patient is different. 14:57 Individualization of therapy is how we will have the best outcomes, 15:01 and the best doctors know that it's worth trying a few things 15:05 before you know you find the one that works. 15:07 And so our technology is about shortening that timeline, 15:11 making it possible to answer that question within a month instead of a year. 15:14 And just have that question be answered. 15:17 I mean, I had grandparents 15:19 who unfortunately passed a Parkinson's and Alzheimer's, and it's 15:24 it's very painful to receive a therapy 15:27 for over a year and have no answers as to whether or not is the right therapy.
Clinical Use and Monitoring 15:31 I mean, there are so many therapies out there, 15:33 and there's also so many types of neuro disease. 15:36 A lot of them look similar. 15:37 Parkinson's looks like Alzheimer's sometimes. 15:39 Very often. 15:40 By the way, answering this question early, creating that feedback loop, 15:44 I think it's going to drive us to a cure. 15:46 But now now I'm going into the aspirational, yeah, yeah. 15:49 No, it was just good for us today is it 15:51 helps you build trust with your patients and show them that the therapy is working, 15:54 or if it's not, you know, try something else. 15:58 Yeah, absolutely. 15:59 Well, I just give a shout out if you're if you're a practitioner, listen to this. 16:03 Definitely. 16:03 Get in touch with James and and check out the site and to, 16:07 you know, test the technology because it's going to take clinicians, 16:10 you know, bringing into their practice for this to scale. 16:13 If you're a patient or a potential patient and ask your doctor 16:17 if Sarah Graham might be right for you to get them involved there 16:20 so that they can see that my understanding is that this is actually already 16:25 payable by insurance. Is that right? 16:28 Yeah, that's a really good question. 16:29 So the hardware that we're using is actually EEG. 16:33 A lot of people don't 16:36 see EEG as an imaging tool. 16:38 And and frankly that that's that's been correct. 16:41 EEG has not been capable of imaging for a very long time since it was invented. 16:46 But yeah, we've come up with a very special technique, 16:48 and it goes beyond the use of AI and algorithms and that type of stuff. 16:53 It's a procedural invention. 16:55 So it changes the way EEG actually works on a fundamental level. 16:59 But the EEG component, the hardware use is reimbursed. 17:03 So for that reason you can go to your doctor. 17:06 You can do this test. 17:08 The doctor can be reimbursed for the procedure. 17:09 But it's I just want to be clear. 17:10 That's not our component that's reimbursed. 17:12 It's the fact that it's the hardware that you're using. 17:14 That's the one that gets reimbursed. 17:17 Yeah, I love that. 17:18 Well, yeah, let's get let's get so the details on 17:21 do you want to do you want to I'd love to actually if you have, some visuals, maybe 17:24 we could see, like, what it looks like and how it compares to Pet scan. 17:28 Yeah, I absolutely would. 17:29 I want to point out 17:30 just so from a regulatory perspective that this is a monitoring technology. 17:35 So if you're planning to use it for a diagnosis 17:38 it is not a diagnosis technology. 17:41 So again monitoring so we're we're we're going to a bunch of conferences 17:45 this year, other conferences that we've been to many times before. 17:49 This is a poster for the, Alzheimer's and Parkinson's Disease conference, EPD. 17:54 It's next month. 17:54 And what you can see here is you can see on the top row, you see Pet scan images. 18:00 And these are for three different patients. 18:02 And on the bottom row you see the output of of the Sarah test. 18:07 We are, you know going after diagnosis as a strategy. 18:11 It's not it's not approved yet. 18:14 So again it's not for diagnosis. 18:16 But you can see from these results that our claims for diagnosis 18:21 are already actually quite strong. 18:23 And so we have some work to do with the FDA before those claims 18:27 are in the product. 18:29 But you can see of just how close this technology matches 18:33 from a structural imaging perspective with PAP. 18:37 And again, this is a EEG. 18:38 These are not you don't just get one slice, you actually get 18:41 all the slices in the brain, just like a normal Pet scan. 18:44 And it's, here we have a metric for evaluating it. 18:47 This is the structural image similarity index. 18:50 And here we put a little C here because it's combined looking at the intensity 18:55 of the of the amyloid proteins and also looking at the gradient. 18:59 So sort of where they're distributed in the brain. 19:02 And we have a similarity score of 0.75 which is incredibly high. 19:08 I mean again you can you can see this for yourself. 19:10 Look at the top image on the bottom image and you can see how closely that 19:13 they match. 19:15 So let me just about this is really cool and I thank you for sharing it. 19:18 I guess what I'm trying to imagine is like a new standard of care 19:22 for cognitive decline and this standard of care, my judgment 19:25 is the type of medicine that's being delivered by Doctor Burke 19:29 and Doctor Sanderson and Doctor Bredesen, you know, is the standard of care 19:33 because it's able to identify what's driving the pathology 19:37 and it's able to catch it early to bring us back to, you know, health 19:42 before we get so far down that we have Alzheimer's as the network 19:46 sort of, brought back to health, it seems as though in that 19:49 if that were to become the standard of care, having some monitoring technology 19:53 that could be deployed, 19:54 you know, every month through the journey back from mild cognitive 19:58 impairment, major cognitive impairment and Alzheimer's, back to health, 20:01 you know, would be helpful for keeping the patient engaged, 20:05 keeping them participatory, and also like tracking the progress back. 20:08 Does that resonate with you? 20:10 Yeah, absolutely. 20:12 My background is in electrical engineering. 20:14 And before this I co-founded a company called durable, 20:18 which is a brain computer interface company. 20:20 One of the things that I've learned, and all of my education, 20:23 is that you need a feedback loop. 20:26 You need a way to measure success. 20:28 The business owners know this. 20:29 You need your your key performance indicators, your metrics. 20:32 If you're not measuring the output 20:35 of your input, then you're working blind. 20:38 And so I think that that's one of the reasons we have such amazing 20:42 physicians like Doctor Berg and Dale Bredesen and, you know, 20:45 several others, but that those physicians are few in number. 20:49 It's because they basically 20:50 have to be magicians in order to apply their techniques. 20:54 They need all of that knowledge that they have that other doctors lack. 20:58 All of that experience, that practical experience with patients 21:02 that other doctors lack. 21:03 It's not scalable, right. 21:05 So if we want to see more physicians finding the same levels of success 21:11 as Doctor Burke had with a recent preprint showing reversal of Alzheimer's, right? 21:16 I mean, it's huge. 21:17 It's happening. It's here. 21:18 Reversal of Alzheimer's. 21:20 If we want more physicians to be able to do that, 21:23 a tool like this is going to simplify the task quite a bit, 21:27 because finally, you can give a treatment and you can see if it's working 21:30 and without that you need your intuition to be very, very, very, very strong 21:36 on pattern 21:37 recognition and history of learning, functional medicine and experience 21:41 of reversing other chronic illnesses that don't have as much, 21:45 you know, unique physiology or as many potential calls. 21:49 The fact 21:49 is, each each one of the physicians out there in the world right 21:52 now, clinicians that is has reversed the case of Alzheimer's, 21:56 is doing incredible work and has an incredible ability 22:00 to be able to do pattern recognition across such a wide variety of biomarker. 22:04 You know, ultimately, our vision through this summit is to introduce
Future Vision for Personalized Care 22:08 those practitioners to true neuro, which is the software that we've developed 22:12 to make it easier for practitioners to synthesize 22:15 that level of data and therefore for it to become the standard of care. 22:19 And that's why I'm really excited about, you know, meeting you 22:21 and connecting with you, 22:22 because I think that we're on the shared mission towards this, that together. 22:26 What do you think? That's why we're we're ideal partners. 22:29 And I'm glad that you called out just how impressive these physicians are, 22:33 because it's true. 22:34 I mean, some of them, you know, they're credentials in several fields of medicine. 22:39 That background in the functional medicine, that background in other areas. 22:42 It's such a difference 22:45 for sure. 22:46 Well, look, let's get aspirational for a moment. 22:48 You know, what are your what are your hopes with the technology. 22:51 And what do you feel is, is the vision that you have for 22:54 for how this technology will affect care? 22:58 Good question. Thank you. 23:00 Thank you. 23:01 My vision is for this technology to start downstream, 23:06 start post screening, post diagnosis. 23:09 You know, I frankly, I don't want to compete with the blood test either, 23:13 because they're doing a ton of marketing, a huge amount of money for that thing. 23:17 So I want to start really downstream. 23:19 And I want to answer the question no one's answering 23:21 is therapy working for this patient? 23:25 So I want to start there. 23:27 But then I do want to move upstream. 23:29 And my vision is that this technology in the future, 23:33 what it will do is it'll match new patients who get their serum 23:37 for the very first time. 23:38 It'll match that patient with the closest patient in our database. 23:43 And look at which treatments those that patient had 23:45 and which treatments were the most successful, and immediately 23:48 suggest treatment options for this patient and even predict what 23:54 the outcome that is expected. 23:56 So if I'm going to use a serum every month, here are three 24:00 different treatments that that have been matched with me through the database. 24:04 And here are three different brain images 24:07 that I should expect to have in a month. 24:10 And so then a month later, I can do a confirmation, 24:13 make sure that the therapy I got was the right one, but also make sure 24:18 that the physician is always, always, always in the driver's seat. 24:22 You know, this is this is not going to be a system, a technology that always tells 24:27 you the right therapy to take the right therapy is for the doctor to decide. 24:31 But it all it'll give you some options and it'll model out what those options 24:35 will look like 24:36 so that the doctor who knows their patient can make those decisions based 24:39 on other therapies they're taking based on allergic reactions they might have. 24:43 Right, based on all of the things that are that are for prescribing treatment. 24:48 And so my vision is that this type of technology 24:51 will become a forcing function for the cure. 24:53 It will accelerate, 24:54 certainly the time to successful treatment and treatment response. 24:58 But what I'm really hoping for is that somebody who is pre-symptomatic 25:03 and use this technology to get a treatment 25:06 that will prevent them from having ever adopting those symptoms. 25:10 I mentioned earlier I was working in BCI. 25:12 I was working in telekinetic wheelchairs. 25:14 That was my my previous vision. 25:17 Everyone can can control wheelchairs with their mind. 25:19 What if nobody needed wheelchairs? 25:22 What if this type of technology 25:23 could be used to prevent neurodegeneration from ever reaching that point? 25:27 And so that's my new vision. 25:29 Thank you for asking. Yeah, I love that. 25:32 Well, look, we're here to support that vision. 25:34 And, really excited to feature you here on this reversing Alzheimer's Summit. 25:38 I think you've got so much to add for, you know, for this conversation. 25:41 And I'm excited to see, you 25:43 know, more opportunities for us to, you know, partner here in the future 25:47 as you continue to refine the technology and have more patients go through it. 25:50 And so, yeah, if you're watching this again, 25:52 if you are, practitioner, check out Sarah Graham, you know, and to be able 25:56 to have something in your office that is, already reimbursable 25:59 if you're doing insurance or can help guide the pro if you're delivering 26:02 brain health programs can help showcase the success of those programs 26:06 and make it easier for patients to see if they're on the journey. 26:09 And then, for patients, 26:10 you know, ask your doctor if Sarah Graham might be right for them. 26:13 Thanks so much for being part of this summit. 26:16 And, we look forward to checking back in with you in the future 26:19 to see how things are going and, seeing how we can be of, 26:23 most value to each other and look forward to other events coming up this year. 26:27 So my name is James Maskell. 26:29 I'm one of the hosts of the Reversing Alzheimer 2.0 summit. 26:33 I been with James Hammett. 26:34 I'll visit him labs 26:36 and we'll have all the details on how you can get in on the on the details below. 26:40 Enjoy the rest of the summit. 26:42 Tune in to something else. 26:43 Awesome today and thanks so much for tuning in. 26:46 Goodbye.
Comments